Skip to search.
 FTSE 100 Up 0.26%

More On SUMM.L

Quotes

Derivatives

  • Warrants
  • Investment Products

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Summit Corp PLC (SUMM.L)

-LSE Ticker: N40HZ0/ISIN: GB00BN40HZ01
138.50 Down 1.50(1.07%) 22 May 16:26
Add to Portfolio
Prev Close:140.00
Open:141.00
Bid:138.25
Ask:138.75
1y Target Est:N/A
Beta:N/A
Next Earnings Date:N/A
Day's Range:136.20 - 141.00
52wk Range:100.00 - 188.00
Volume:30,125
Avg Vol (3m):98,113
Market Cap:84.46m
P/E (ttm):N/A
EPS (ttm):-0.30
Div & Yield:N/A (N/A)
Trade Now
Quotes delayed, except where indicated otherwise. Currency in GBp.

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):N/A
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Jan-16) :-25.60
Quarterly EPS Est (0-00-31) :N/A
Mean Recommendation*:1.5
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focusses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DM... more
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback